Dupilumab is a fully human monoclonal antibody that inhibits the activity of both interleukin (IL)-4 and IL-13, which play a key role in type 2 inflammation in multiple diseases, including bullous pemphigoid (BP)

In recent case report studies, dupilumab successfully treated patients with recalcitrant moderate-to-severe BP

LIBERTY-BP ADEPT (NCT04206553) is an ongoing, randomized, phase 2/3 clinical trial designed to assess the efficacy and safety of dupilumab in patients with moderate-to-severe BP

LIBERTY-BP ADEPT will enroll approximately 98 patients from 51 global sites in 4 continents (North America, Europe, Australia and Asia)